Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-7. doi: 10.1016/j.diagmicrobio.2010.10.031.
Two novel lipoglycopeptides, dalbavancin and telavancin, and relevant comparative agents were tested for in vitro activity against clinical isolates of staphylococci and streptococci collected in the cross-Canada surveillance study, CANWARD, in 2007-2009. The rank order of potency (based on MIC(90) [μg/mL], i.e., the concentration of antimicrobial agent required to inhibit the growth of 90% of isolates tested) of glycopeptides against both Staphylococcus aureus and Staphylococcus epidermidis was dalbavancin (0.06 μg/mL) >telavancin (0.5 μg/mL) > vancomycin (1-2 μg/mL); concurrent susceptibility or resistance to oxacillin in staphylococci did not affect potency of glycopeptides. Dalbavancin and telavancin also demonstrated potent activity against Streptococcus pneumoniae, including penicillin-resistant isolates (MIC(90), ≤ 0.03 μg/mL; ≤ 0.06 μg/mL), and Streptococcus pyogenes (≤ 0.03 μg/mL; 0.06 μg/mL). Based on their robust in vitro activities, dalbavancin and telavancin have the potential to treat Gram-positive infections caused by methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
两种新型糖肽类抗生素，达巴万星和替考拉宁，以及相关的比较药物，在 2007-2009 年的加拿大跨地区监测研究（CANWARD）中，针对分离自临床的葡萄球菌属和链球菌属的菌株进行了体外活性测试。糖肽类药物对金黄色葡萄球菌和表皮葡萄球菌的效力（基于 MIC90[μg/mL]，即抑制 90%测试分离株生长所需的抗菌药物浓度）的排序为：达巴万星（0.06μg/mL）>替考拉宁（0.5μg/mL）>万古霉素（1-2μg/mL）；葡萄球菌属对苯唑西林的同时敏感性或耐药性并不影响糖肽类药物的效力。达巴万星和替考拉宁对肺炎链球菌也具有强大的活性，包括对青霉素耐药的分离株（MIC90，≤0.03μg/mL；≤0.06μg/mL）和化脓性链球菌（≤0.03μg/mL；0.06μg/mL）。基于其强大的体外活性，达巴万星和替考拉宁有可能治疗耐甲氧西林金黄色葡萄球菌和青霉素耐药肺炎链球菌引起的革兰氏阳性感染。
